Premium
Ozagrel increases retinal arteriolar diameters in streptozotocin (STZ) ‐ induced diabetes
Author(s) -
Wright William S.,
Harris Norman R.
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.6.a844-b
Subject(s) - retinal , vasoconstriction , streptozotocin , diabetes mellitus , intravital microscopy , retina , constriction , thromboxane a2 , medicine , microcirculation , chemistry , endocrinology , biology , biochemistry , platelet , neuroscience
It has been reported that vasoconstriction occurs in the diabetic retina, although the mechanisms remain unknown. The objective of these experiments was to determine the role of thromboxane (TxA 2 ) in vasoconstriction at early time points in the diabetic retina. Male C57BL/6J mice were injected with STZ (200 mg/kg) at 12 weeks of age and remained diabetic 4 weeks. Age‐matched control mice were injected with vehicle alone. Upon visualization of the retina via intravital microscopy, the arterioles leading out of the optic disc were measured. Ozagrel (100 mg/kg), a TxA 2 synthase inhibitor, was infused at a rate of 20 μl/min, and arteriolar diameters were re‐measured 25 min following the start of infusion. Arteriolar diameters of diabetic mice before ozagrel were 13% smaller than in controls (p<0.0001), diameters after ozagrel were not different (2%, p=.57). Regression analysis showed a significant correlation between baseline diameter and percent change in diameter following ozagrel (p< 0.001, r 2 = 0.41), that is, the most constricted vessels responded most to the ozagrel. The results suggest a role for TxA 2 in the retinal arteriolar constriction induced by STZ. Supported by JDRF 1‐2003‐159.